Volume 92, Issue 1, Pages (July 2017)

Slides:

Advertisements

Similar presentations

Volume 58, Issue 1, Pages (July 2000)

Advertisements

Volume 85, Issue 4, Pages (April 2014)

Volume 66, Issue 1, Pages (July 2004)

Volume 69, Issue 5, Pages (March 2006)

Volume 93, Issue 2, Pages (February 2018)

Volume 92, Issue 5, Pages (November 2017)

Volume 85, Issue 4, Pages (April 2014)

Volume 91, Issue 4, Pages (April 2017)

Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients Demetrios J. Kutsogiannis, R.T.Noel.

Volume 93, Issue 2, Pages (February 2018)

Membranous nephropathy: When and how to treat

M. Kats, A.M. Hawxby, J. Barker, M. Allon Kidney International

Outcomes of Allogeneic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia: A Systematic Review and Meta-analysis Armin Rashidi,

Mycophenolate mofetil treatment for primary glomerular diseases

The risk of hospitalization and modality failure with home dialysis

Prolonged warm ischemia time is associated with graft failure and mortality after kidney transplantation Karthik K. Tennankore, S. Joseph Kim, Ian P.J.

Mycophenolate therapy of SLE membranous nephropathy

Volume 73, Issue 4, Pages (February 2008)

Steroid-free maintenance immunosuppression in kidney transplantation: is it time to consider it as a standard therapy? Fu L. Luan, Diane E. Steffick,

Volume 61, Issue 3, Pages (March 2002)

Volume 55, Issue 1, Pages (January 1999)

Comorbidity and confounding in end-stage renal disease

Volume 70, Issue 11, Pages (December 2006)

What really happens to people on long-term peritoneal dialysis?

Volume 65, Issue 2, Pages (February 2004)

Volume 85, Issue 6, Pages (June 2014)

Volume 84, Issue 5, Pages (November 2013)

M. Kats, A.M. Hawxby, J. Barker, M. Allon Kidney International

Volume 61, Issue 4, Pages (April 2002)

Volume 87, Issue 1, Pages (January 2015)

Volume 85, Issue 3, Pages (March 2014)

Volume 73, Issue 10, Pages (May 2008)

Volume 375, Issue 9719, Pages (March 2010)

Volume 62, Issue 1, Pages (July 2002)

Volume 87, Issue 1, Pages (January 2015)

Volume 89, Issue 5, Pages (May 2016)

Volume 82, Issue 10, Pages (November 2012)

Volume 85, Issue 5, Pages (May 2014)

Volume 69, Issue 12, Pages (June 2006)

Volume 69, Issue 3, Pages (February 2006)

Abdulla K. Salahudeen, Erwin H. Fleischmann, John D. Bower

Alternate-day dialysis may be needed for hemodialysis patients

Volume 93, Issue 1, Pages (January 2018)

Volume 66, Issue 6, Pages (December 2004)

Simvastatin in nephrotic syndrome

Volume 67, Issue 5, Pages (May 2005)

Volume 71, Issue 4, Pages (February 2007)

Higher serum C-reactive protein predicts short and long-term outcomes in peritoneal dialysis-associated peritonitis N.-Y. Zalunardo, C.-L. Rose, I.W.Y.

Volume 67, Issue 3, Pages (March 2005)

Volume 66, Issue 3, Pages (September 2004)

Volume 63, Issue 2, Pages (February 2003)

Volume 57, Issue 1, Pages (January 2000)

Acute renal failure independently predicts mortality after myeloablative allogeneic hematopoietic cell transplant Chirag R. Parikh, Peter Mcsweeney,

Preemptive kidney transplantation is associated with survival benefits among pediatric patients with end-stage renal disease Sandra Amaral, Blayne A.

Volume 64, Issue 4, Pages (October 2003)

Charles A. Herzog Kidney International

Volume 62, Issue 5, Pages (November 2002)

Volume 75, Issue 1, Pages (January 2009)

Importance of blood pressure control in hemodialysis patient survival

Yutaka Koda, M.D., Shin-Ichi Nishi, Masashi Suzuki, Yoshihei Hirasawa

Volume 55, Issue 2, Pages (February 1999)

Volume 59, Issue 5, Pages (May 2001)

Collecting and using patient and treatment center data to improve care: Adequacy of hemodialysis and end-stage renal disease surveillance1 William M.

The changing face of childhood nephrotic syndrome

Volume 64, Issue 4, Pages (October 2003)

Volume 82, Issue 9, Pages (November 2012)

Dana V. Rizk, David G. Warnock Kidney International

Prediction in idiopathic membranous nephropathy

Volume 60, Issue 2, Pages (August 2001)

Volume 77, Issue 2, Pages (January 2010)

Presentation transcript:

Volume 92, Issue 1, Pages 248-257 (July 2017) Mycophenolate mofetil is inferior to tacrolimus in sustaining remission in children with idiopathic steroid-resistant nephrotic syndrome Aditi Sinha, Aarti Gupta, Mani Kalaivani, Pankaj Hari, Amit K. Dinda, Arvind Bagga Kidney International Volume 92, Issue 1, Pages 248-257 (July 2017) DOI: 10.1016/j.kint.2017.01.019 Copyright © 2017 International Society of Nephrology Terms and Conditions

Figure 1 Study flow. All patients were included in the modified intention-to-treat analysis. Kidney International 2017 92, 248-257DOI: (10.1016/j.kint.2017.01.019) Copyright © 2017 International Society of Nephrology Terms and Conditions

Figure 2 Kaplan-Meier estimates of relapse free–survival (a) and survival free of treatment failure (b). Similar proportions of patients receiving mycophenolate mofetil (MMF) and tacrolimus were in sustained remission at 6 months (58.6% vs. 67.7%) and at 1 year (41.1% vs. 54.8%) (log rank P = 0.24). The proportions of patients with treatment failure were significantly higher for patients receiving MMF than tacrolimus at 6 months (31% vs. 0%) and 1 year (52% vs. 9.7%) (log rank P = 0.0001). Kidney International 2017 92, 248-257DOI: (10.1016/j.kint.2017.01.019) Copyright © 2017 International Society of Nephrology Terms and Conditions

Figure 3 Subgroup analysis of patients treated with mycophenolate mofetil versus tacrolimus in the entire group and in subgroups defined a priori and potential confounders. Plots for relative risk of favorable outcome (a) and hazard ratio for treatment failure (b) demonstrate a significantly lower relative risk of favorable outcome and increased risk of treatment failure in most subgroups. *Hazard ratio could not be computed because of lack of events in the tacrolimus group. Kidney International 2017 92, 248-257DOI: (10.1016/j.kint.2017.01.019) Copyright © 2017 International Society of Nephrology Terms and Conditions